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The adverse effects and choice of injectable agents in MDR-TB: amikacin or capreomycin 
Abstract 
Background: The prolonged use of injectable agents in an MDR-TB regimen is recommended 
by the WHO despite association with ototoxicity and nephrotoxicity.  
Objective: We undertook this study to look at the relative adverse effects of capreomycin and 
amikacin.  
Methods: We reviewed the case notes of 100 consecutive patients treated at 4 MDR-TB 
treatment centres in the UK.  
Results: The median total duration of treatment with an injectable agent was 178 (IQR 109-
192, n=73) days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB plus 
fluoroquinolone resistance and 558 (324-735, n=8) days for those with XDR-TB. Injectable use 
was longer for those started with capreomycin at 183 (IQR 123-197) days compared to 119 
(IQR 83-177) days with amikacin (p=0.002). Excluding XDR-TB, 51 (51/85, 60%) patients were 
treated with an injectable for over 6 months and 12 (12/85, 14%) for over 8 months. 40 % of 
all patients discontinued the injectable due to hearing loss. 55% of patients experienced 
ototoxicity: 5 times (hazard ratio (HR) 5.2, CI 1.2-22.6, p=0.03) more likely in those started on 
amikacin compared to treatment with capreomycin only. Amikacin was associated with less 
hypokalemia than capreomycin (Odds ratios: 0.28 (0.11-0.72)), with 5 (5/37, 14%) patients 
stopping capreomycin due to recurrent electrolyte loss. There was no difference in the 
number experiencing a creatinine rise of > 1.5 times baseline.  
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Conclusion: Hearing loss is frequent in this cohort, though significantly lower in those starting 
capreomycin which should be given greater consideration as a first line agent.  
Main Text 
Introduction 
Treatment of multidrug resistant tuberculosis (MDR-TB) is challenging requiring extensive 
multidrug combinations for up to two years associated with significant adverse effects(1) 
Current treatment for MDR-TB is largely dependent on the World Health Organisation (WHO) 
guidelines(2-4)  which are based on cohort, meta-analysis data and expert opinion. These 
recommend that all patients should be initially (intensive phase) treated with an injectable 
agent in the form of an aminoglycoside (kanamycin/amikacin) or polypeptide (capreomycin). 
The duration of the intensive phase recommended by the WHO rose from a minimum of 6 
months to 8 months in 2011(3, 4) with even longer durations recommended for cases with 
more extensive resistance.  The recommendation was based on a large meta-analysis of 
patient outcomes and did not take into account the side effects or other costs of these 
drugs.(5)  
The injectable agents have significant side effects in the form of permanent and potentially 
progressive post cessation ototoxicity and usually reversible nephrotoxicity. (6-9) The 
frequency of ototoxicity and nephrotoxicity experienced by patients varies between studies, 
and most focus on the side effects of the aminoglycosides rather than the polypeptide, 
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capreomycin. Limited evidence suggests that capreomycin may be less ototoxic than 
amikacin.(10) 
No randomised controlled trial of different injectable agents has been performed but better 
data is needed to inform policy. We performed a detailed service evaluation cohort study 
within four specialist UK MDR-TB treatment centres to compare the outcomes with different 
injectable agents in a real world setting. 
Methods 
 
Setting 
Retrospective data were collected through clinical records and hospital database review at 4 
tuberculosis (TB) treatment centres; St Mary’s Hospital, Imperial College NHS Trust, London 
(centre 1), Heartlands Hospital, Birmingham (centre 2), the Royal Free Hospital, London 
(centre 3), St George’s Hospital, London (centre 4). These centres act as regional referral hubs 
for MDR-TB treatment . Data were also collected at referring hospitals if patients were treated 
under a shared care model. Standard definitions were used for MDR-TB and extensively drug 
resistant tuberculosis (XDR-TB), pulmonary (PTB), extra pulmonary tuberculosis (EPTB)(11) 
and treatment was based on the WHO guidelines.(2, 3) At sites 1-2 amikacin is the preferred 
injectable agent, site 3 uses a mix and site 4 predominantly uses capreomycin (all 
intravenous).  All sites switched injectable at the physician’s discretion. All injectable agents 
are dosed initially at 15mg/kg once a day with trough drugs levels for amikacin at least weekly. 
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Reduced frequency of dosing is used if side effects occur. Duration of 6 months or more was 
defined as over 160 days and duration of 8 months was defined as over 220 days. 
Study population and eligibility criteria 
The first 100 consecutive patients, over 14 years of age, with a diagnosis of MDR-TB made in 
the UK, initiating MDR-TB treatment at the four sites between 2008 and 2014, were reviewed. 
Seven patients were excluded due to: lack of injectable agent use (2), streptomycin use at 
start (2), and over three initiations on MDR-TB medications (n=3). The cohort was split into 
two according to date of treatment start (the 51st patient started treatment in spring 2011) 
which corresponded to the change in WHO advice regarding injectable duration. 
 
Renal function monitoring 
To be included in analysis of renal function patients required at least weekly blood results 
available for review. Renal impairment was defined as mild at 1.5 times baseline creatinine 
and severe at over 3 times baseline(12). Hypokalaemia was defined as any drop below 
3.5mmol/L.(13) Hypomagnesaemia was defined as any measurement below 0.7mmol/L.(12) 
Audiological monitoring 
All patients underwent pure tone audiometry (PTA) performed to the standards of the British 
Society of audiology (14) at the start of the injectable therapy. All sites performed PTA if 
hearing loss/change symptoms/any concern about hearing arose on treatment and sites 1, 2 
and 3 had a policy of monthly PTA in addition (limited by patient adherence to protocol). 
Centre 3 performed audiograms at frequencies above 9- 20khz for a proportion of the study 
period. Significant deterioration between audiograms was determined by the American 
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speech and hearing association (ASHA) criteria which were as follows for frequencies tested 
between 250-8khz: (i) 20dB decrease ay any one test frequency, (ii) 10 dB decrease at any 
two adjacent frequencies, (iii). Loss of response at any three adjacent frequencies where 
responses were previously obtained .(15) Two end points relating to hearing were chosen: an 
audiogram definition (ototoxicity) and a composite definition encompassing audiogram 
results and clinically reported hearing loss (hearing loss (composite)) (Table 1). Patient 
reported ‘hearing impairment’ was defined as any report by the patient of a negative change 
in hearing while on injectable agents or after stopping the injectable as documented by a 
nurse or doctor. ‘Tinnitus’ was defined as any symptoms reported by the patient that were 
interpreted as tinnitus by a doctor or nurse and documented in the records. Reasons for 
stopping injectable agents were collated from the medical notes according to what was 
written by the consultant in charge of treatment.  
 
Statistics  
Patients were grouped according to the injectable agent they were exposed to: 1. 
capreomycin only, 2. amikacin start (includes those only treated with amikacin and those 
treated with amikacin and switched to capreomycin or streptomycin because hearing loss was 
the main driver of this switch), 3. capreomycin then switch to amikacin (none switched due 
to hearing loss). Hearing loss was analysed within survival settings using Cox proportional 
hazard models, modelling the time since treatment start to point of hearing loss. Raised 
creatinine and hypokalaemia were investigated using logistic regression. Univariate analyses 
were initially undertaken which included all variables collected (age, gender, baseline 
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creatinine, baseline creatinine clearance (Cockroft Gault equation), dose of drug, MDR-TB 
type, number of amikacin troughs, centre, and amikacin and capreomycin group). 
Associations with resulting p-values less than 0.1 were further considered to form a 
multivariable/adjusted models based on similar numbers of complete observations. Model 
selection was undertaken by choosing the most parsimonious model using Akaike information 
criteria (AIC) and Bayesian information  criteria (BIC). The final models were further refined 
using multiple imputation methodologies assuming missing at random model   to account for 
approximately 15% of the original data that  was missing (16). Further details on statistical 
methodologies are given in appendix 1. STATA software was employed for data analyses 
(StataCorp.2015 Stata Statistical Software: Release 14. College Station, TX:StataCorp LP).  
 
Ethics 
The study was deemed to be a service evaluation at the NHS ethics board (NRES committee 
London- City and East). Consent was given by the Confidentiality Advisory Group (GAG) for 
access to clinical records review. The data were anonymised onsite for off sites analyses. 
 
Results  
Fifty-four patients were started on amikacin and 39 were started on capreomycin (total, 
n=93). Nineteen patients switched injectable agent for the reasons stated in Figure 1. 
Background demographics and tuberculosis characteristics can be seen in Table 2.  
Total duration of treatment with an injectable agent 
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The median total duration of treatment with an injectable agent was 178 (IQR 109-192, n=73) 
days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB plus 
fluroquinolone resistance (MDR-TB +FLQ) and 558 (324-735, n=8) for those with XDR-TB.  
 
Excluding those with XDR-TB, 51 (51/60, 60%) patients were treated for 6 months or more 
and 12 (12/85, 14%) for 8 months or more. In the early cohort the median duration of 
treatment was 165 (107-187, n=42) days, of which 23 (23/42, 55%) achieved the target of 6 
months and 3 (3/42, 7%) were treated for 8 months plus. In the latter cohort the median 
duration of treatment was 183 (109-210, n=43) days, of which 28 (28/43, 65%) were treated 
for 6 months or more and 9 (9/43, 21%) achieved the target of 8 months or more. There was 
no statistical difference in duration between the early and late cohort (p=0.19).  
Seven (7/8, 87%) patients with XDR-TB were treated for 6 months or more and 6 (6/8, 75%) 
for 8 months or more.  
The reasons for not achieving 6 months of treatment or more for all groups of patients were 
hearing loss (composite) 14 (14/35, 40%), physician choice 8 (8/35, 23%), resistance 4 (4/35, 
11%), compliance concerns 3 (3/35, 9%) other 6 (6/35, 17%).  
The median duration of the first line injectable agent was 160 (IQR 91-186) days for all 
patients. The median total duration was 183 (IQR 123-197) days for those started on 
capreomycin and 119 (IQR 83-177) days for those started on amikacin (p=0.002). 
Ototoxicity 
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The proportion of cases that met the criteria for ototoxicity assessment was 55 (55/93, 59%) 
(Table 1) of whom 39 were started on amikacin and 16 started on capreomycin. Clinical notes 
were available for all 55 patients.  Ototoxicity occurred in 30 patients (30/55, 55%), at a 
median duration of 112.5 days (IQR 91-177) and 18 (18/55, 60%) had bilateral changes. 
Deterioration was seen at the frequencies 6 -8 kHz only in 19 (19/55, 63%) cases, in the 
frequencies 4-8kHz only in 3 (3/55, 10%) cases, in frequencies 2-8kHz only in 6 (6/55, 20%) 
cases and across all frequencies tested (250Hz-8kHz) in 2 (2/55, 7%) cases. The median 
maximum change from baseline hearing at the worst effected frequency was 40 dB (IQR 25-
55).  At the time that ototoxicity was detected 8 (8/55, 27%) patients reported new onset 
hearing disturbance and tinnitus, 8 (8/55, 27%) reported tinnitus only, 3 (3/55, 10%) reported 
hearing disturbance only and 11 (11/55, 37%) did not report any symptoms. 
 
Ototoxicity occurring on Amikacin 
Twenty-eight cases of ototoxicity occurred while on treatment with amikacin (n=23) or after 
stopping treatment with amikacin (n=5). The median total number of amikacin trough levels 
did not differ between those with ototoxicity (1.03 IQR 0.77-1.28) and those without (1.21 
IQR 1-1.43) (p=0.10). The proportion of one or more amikacin trough levels above 2.5 was 
12/28 (40%) for those with ototoxicity and 5/14 (36%) for those treated with amikacin and no 
ototoxicity (P=0.66).  
 
3 cases experienced ototoxicity on amikacin and had initially been treated with capreomycin. 
They had been switched to amikacin due to electrolyte disturbance (n=2) or resistance (n=1). 
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Two of the patients had normal audiograms (and same as their baseline) at the time of switch 
(174 and 164 days) and the third had a normal audiogram at the start of capreomycin followed 
by an abnormal audiogram after 282 days of amikacin treatment when newly reported 
tinnitus lead to testing. Fifteen (15/28, 54%) patients had sufficient audiograms to assess 
deterioration after stopping amikacin; 10 (10/15, 67%) progressed, 1 (1/28, 7%) improved and 
4 (4/15, 27%) did not change. 
 
Ototoxicity occurring on Capreomycin 
Two cases of ototoxicity occurred on capreomycin. Both were in patients with XDR-TB in 
whom stopping the regimen would have reduced the number of active drugs below 4 and so 
despite early detection, treatment was continued with monitoring. Neither case experienced 
any permanent symptoms. Both cases had normal audiograms on first assessment and 
sensorineural hearing loss was identified on the second audiogram to be performed after the 
baseline which was at day 33 (performed due to vague symptoms of muffled hearing which 
went away) and day 112 (performed for screening no symptoms) of treatment respectively. 
Changes were seen bilaterally in both cases at the 6KHz and 8KHz frequency. There was a 
drop of 10-20db in case 1 and a drop of 30-55db in case 2. A further 3 and 4 audiograms were 
performed until days 434 (case 1) and 447 (case 2) of treatment and no further deterioration 
was seen. Both patients continued treatment after this period of monitoring with no change 
in symptoms but no further audiograms were performed.
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Multivariable analysis using only the patients who fitted the ototoxicity criteria showed that 
ototoxicity was five times more likely for patients started on amikacin than for those treated 
with only capreomycin (HR 5.2, CI 1.2-22.6, p=0.03). 
 
Hearing loss (composite) 
Three patients (3/93) did not have sufficient medical notes (n=1) or could not express loss of 
hearing (psychosis n=1, intubated n=1) to be included in this analysis. Thirty-four (34/90, 38%) 
of those meeting criteria for inclusion experienced hearing loss (composite). The multivariable 
analysis showed that the likelihood of hearing loss (composite) was 14 times greater for 
patients started on amikacin compared to those treated with capreomycin only (Hazard ratio 
13.9  CI 3.25-59, P<0.001) (Table 3) . Predicted survival analysis also showed that the 
probability of not developing hearing loss beyond 90 days was 0.99 (0.95- 1.00) in those on 
capreomycin only compared to 0.85 (0.73-0.92) for those starting amikacin. Furthermore the 
probability of surviving without hearing loss beyond 180 days was 0.97 (0.86-0.99) for those 
on capreomycin only compared to 0.58 (0.41, 0.72) for those started on amikacin (Figure 2).   
 
Nephrotoxicity 
Over the first 3 months renal function monitoring was performed a median of 19 times (IQR: 
14-25) and over months 4-6, 9 times (IQR: 4-15).  
 
Raised creatinine 
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Eighty-five cases had complete set of creatinine blood results. 25% (21/85) had a rise of 1.5 
times or more from baseline of which 3 (3.5% =3/85) had a rise of 3 times baseline. The 
creatinine returned to baseline (under 1.5 times normal) in 19 (19/21) cases, 16 before the 
end of the injectable and 3 before the end of MDR-TB treatment. In patients where the 
creatinine did not return to baseline; one required haemodialysis after the amikacin was 
stopped (he already had chronic kidney disease at the start of therapy for MDR-TB and a 
baseline creatinine of 313 µmol/L which peaked at 846µmol/L) and the other due to death 
from advanced HIV (CD4=5). A multivariable model including baseline creatinine, duration on 
injectable agent and choice of injectable agent at start showed that there was no significant 
difference in the odds of raised creatinine between the two injectable agents chosen at the 
start (p=0.178) when adjusted for the total duration of the treatment. However, some 
evidence suggests that increasing duration may increase the odds of raised creatinine, i.e. 30 
days increase is associated with 15% (95%CI(25, 32%)) raise in the odds of raised creatinine 
(p=0.04)  (Table 4).  
 
Electrolyte disturbance 
 
Eighty-six patients  had a complete set of potassium results, 37 started on capreomycin and 
49  amikacin. Hypokalaemia was found in 38 (38/86, 44%) patients while on an injectable 
agent: 23 (23/38, 61%) were on capreomycin and 15 (15/38, 39%) amikacin.Eighteen cases 
(18/38) resolved alone without potassium replacement.  Seventeen required replacement 
with oral potassium (13/17 on capreomycin), 7 required replacement with intravenous 
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potassium (all capreomycin), 4 had their dose reduced to 3 times per week (all capreomycin) 
and 3 required a switch in injectable agent (all capreomycin to amikacin). A multivariable 
model including duration of injectable agent and initial injectable agent indicated that the 
odds of hypokalaemia were approximately 4 times lower in those starting amikacin than for 
those starting capreomycin (Odds ratios: 0.28 (0.11-0.72). (Table 4) 
 
Regular magnesium testing was performed for 15 of the capreomycin and none of the 
amikacin patients. Thirteen  (13/15) were hypomagnesemic (11/13 with a reading below 0.5 
mmol/L) of which 10 were treated with oral replacement, 9 with intravenous replacement 
and 4 required a switch to amikacin (3 of these also had reduced potassium and are inclusive 
of the 3 above). One stopped injectable earlier than planned due to hypomagnesaemia.  
 
Switching from capreomycin to amikacin or stopping capreomycin early for electrolyte 
disturbance occurred in 5 patients (5/37) at a median of 132 (range 53-207, n=5) days. Of the 
four cases switched from capreomycin to amikacin one subsequently suffered ototoxicity on 
amikacin.  
 
Discussion 
We present data showing that ototoxicity is very frequent and that in England a third of 
patients do not reach the original 2008 WHO treatment guideline advising at least 6 months 
of an injectable agent. Even fewer reach the newer target of 8 months for the intensive phase. 
In a sub-cohort analysis capreomycin is associated with less ototoxicity and/or hearing loss 
14 
 
than amikacin though its use is sometimes limited by electrolyte disturbance. Those starting 
capreomycin were also able to tolerate injectable treatment for much longer.  
Hearing loss during MDR-TB treatment is reported to be anywhere between 4.4% (1, 17)and 
62% (18) (19) dependent on duration, drug choice, dose(6) and type of monitoring. Studies 
with a clinical definition (patient reporting symptoms) show lower levels than those with an 
audiogram based definition (20) and the majority of studies have been performed in the 
presence of the aminoglycosides, amikacin or the more commonly used worldwide and 
closely related kanamycin (15mg/kg/day). Our level of 55% ototoxicity is similar to the 
findings of others using intense monitoring and aminoglycosides at 15mg/kg, (15) (7, 18, 19, 
21) Retrospective cohort analysis suggests that Kanamycin use is associated with less 
ototoxicity than amikacin. (21)    
There are few recent MDR-TB studies investigating hearing loss associated with capreomycin 
possibly as its cost and need for electrolyte monitoring put it out of reach for many low 
income countries. However, although clearly defined methods for monitoring are not always 
described, there is a suggestion that levels of hearing loss are lower for capreomycin with 
proportions affected ranging from 0.7%-25%.(6, 22-25) Studies comparing amikacin to 
capreomycin are limited to a small retrospective study by this group which showed in 
univariate analysis that hearing loss was associated with amikacin use over capreomycin(10) 
and a pharmacovigilance reporting study showing spontaneous reports of deafness were 
disproportionately associated with amikacin followed by kanamycin compared to 
capromycin. (26)  Our study has larger numbers than our earlier study and is not limited by 
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reporting bias and other issues inherent in pharmacovigilance reporting. The main limitation 
of our study arises from the differing audiogram policies at the sites. In the hearing loss 
(composite) analysis there is the possibility of underestimating hearing loss caused by 
capreomycin due to asymptomatic cases with ototoxicity being less likely to be identified 
(ascertainment bias) than those in the amikacin group who had more routine audiograms. 
However, to counter this possible bias we performed the ototoxicity analysis including in the 
denominators only those who had had an audiogram within a month of ending the injectable 
agent. Although the numbers of patients is smaller, in this analysis, the possible bias works in 
the opposite direction because patients at capreomycin sites who had audiograms were more 
likely to be those with a perceived risk of ototoxicity. These issues probably account for the 
difference between the hazard ratio for the ototoxicity outcome (5 times more likely with 
amikacin) compared to 15 times more likely for the composite hearing loss outcome with 
amikacin, and the real value may lie between the two numbers.  We also consider that the 
character as well as the likelihood of occurrence of hearing loss can differ with capreomycin. 
The evidence for this suggestion is that the audiograms of the two patients who experienced 
ototoxicity on capreomycin did not display progressive hearing loss despite on-going 
exposure (lack of alternative drugs) which would be extremely unlikely for amikacin. (8) 
However, further investigations on the type of and degree of hearing loss caused by 
capreomycin in a randomised controlled trial is required. Reducing the proportions of patients 
experiencing hearing loss treated with amikacin may be possible with lower doses (7.5mg/kg) 
and AUC monitoring. (27) However the efficacy of this dose is unclear and it is not currently 
recommended.  Other possibilities include the co-administration of N-acetyl cysteine or other 
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antioxidants,(28) and genetic testing for mutations in the mitochondrial gene encoding 12S 
rRNA (MT-RNR1) and avoiding aminoglycosides in these cases, (29-31) though the prevalence 
of these mutations is low.  
However, our findings support the initial use of capreomycin over amikacin as a means of 
reducing hearing loss. Capreomycin use first line has also been advocated for, when onwards 
resistance patterns are considered; amikacin activity is often spared after the evolution of 
capreomycin resistance but not the other way round.(32, 33)  The disadvantage of 
capreomycin is the associated electrolyte disturbance which led to discontinuation/switch in 
14% of patients treated with it in our study. Of note, however, electrolyte abnormalities were 
managed effectively in all patients with no long term consequences. The association of 
capreomycin with electrolyte disturbance and renal impairment during treatment for TB is 
well reported. (13, 34, 35) In settings where regular rapid and reliable blood monitoring is not 
feasible, the nephrotoxicity of capreomycin may lead to deaths due to hypokalaemia and 
renal failure.(13, 23) Our data demonstrate that this is not the case in a well-resourced 
setting. 
In summary we provide retrospective cohort evidence of high levels of ototoxicity and hearing 
loss in a UK MDR-TB cohort. Hearing loss was 14 times more likely with amikacin than 
capreomycin, while capreomycin was associated with electrolyte disturbance leading to 
cessation of the drug in 14% of those treated with it.  Given the significance and  irreversibility 
of hearing loss, in settings where blood monitoring is possible, we would favour starting with 
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capreomycin rather than amikacin, until such time as short course and injectable drug -free 
regimens incorporating the newer drugs have been shown to be effective .(17) 
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 Table 1: Ototoxicity and Hearing loss (composite) definitions 
 
 Hearing loss No hearing loss Unable to classify 
Ototoxicity 
 
 
 
A significant deterioration (as 
determined by ASHA criteria) 
between an audiogram performed 
before or during therapy and one 
performed later during therapy or 
after completing therapy in the 
presence of normal 
tympanograms.* 
A normal audiogram in the last 
month or after completing 
injectable therapy.* 
An abnormal audiogram 
without an earlier audiogram 
for comparison* 
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 No significant deterioration (ASHA 
criteria) between an audiogram 
performed in the last month or after 
injectable therapy stopped and one 
performed within the first month of 
therapy.*  
A normal final audiogram 
before the last month of 
therapy (unless performed 
after 365 days on therapy). 
No significant deterioration (ASHA 
criteria) between an audiogram 
performed after 365 days of 
injectable therapy and one 
performed within the first month of 
therapy. 
Hearing loss (composite)  
 
 
 
As for ototoxicity No report of ‘hearing impairment’ or 
‘tinnitus’ and does not fit the criteria 
for ototoxicity. 
Unable to report symptoms 
(intubated, extreme psychosis) 
or full set of medical or nursing 
notes missing. 
A clinical report of new ‘hearing 
impairment’ or ‘tinnitus’ during or 
after therapy with an injectable 
agent in association with an 
abnormal audiogram. No prior 
audiogram required.   
A clinical report of new ‘hearing 
impairment’ or ‘tinnitus’ during or 
after therapy with an injectable 
agent in association with a normal 
audiogram or no deterioration in 
audiograms performed within a 
month of starting and at the time or 
after the onset of symptoms.  
 
A clinical report of new ‘hearing 
impairment’ or ‘tinnitus’ during or 
after therapy with an injectable 
agent in association with a 
significant deterioration (ASHA 
criteria)  between an audiogram 
performed before or during therapy 
and one performed later during 
therapy or after completing therapy 
above 8khz range.  
  
Worsening ototoxicity 
after stopping injectable 
agent 
A significant deterioration (as 
determined by ASHA criteria) 
between an audiogram performed 
30 days or more after the end of 
injectable therapy to one 
performed in the month before the 
end of therapy or on the stop date. 
No significant deterioration (as 
determined by ASHA criteria) 
between an audiogram performed 
30 days or more after the end of 
injectable therapy to one performed 
in the month before the end of 
therapy or on the stop date. 
Any case not fitting either of 
the definitions.  
PTA= pure tone audiometry, Normal audiogram=all frequencies better than 25 dB, abnormal 
audiogram = ASHA criteria, ASHA=American speech and Hearing Association. *based on 
definitions of hearing loss proposed by Seddon et al 20129  
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Table 2: Background characteristics and demographics of patients (n=93) 
Characteristic Number (% unless otherwise indicated) 
Median age in months (IQR*) (n=93)  28 (24-38) 
Male gender (n=93)  64 (68) 
HIV infected (n=93)  5 (5) 
Country of birth (n=93) UK 9 (10) 
 Western and Northern Europe other  1 (1) 
 Chinese subcontinent 10 (10) 
 Indian subcontinent 36 (38) 
 Africa 15 (16) 
 Eastern Europe + Russia 22 (24) 
Type of TB (n=93) MDR-TB 73 (78) 
 MDR-TB +FLQr**  12 (13) 
 XDR-TB 8 (9) 
Location of TB (n=93) Pulmonary 41 (44) 
 Extra-pulmonary only 31 (33) 
 Both pulmonary and extra-pulmonary 21 (23) 
Injectable agent (n=93) Capreomycin 31 (33) 
 Amikacin 43 (46) 
 Amikacin and capreomycin (sequentially, 
either order) 
18 (19) 
 Amikacin followed by streptomycin  1 (1) 
Baseline creatinine µmol/L (n=87)(IQR)  66 (58-75) 
Creatinine clearance (n=81, median/IQR)  116.2 (75.7, 179.1) 
Median initial dose of injectable agent 
(mg/kg) (n=82) (IQR) 
 14.81 (14.06-16.13) 
Median number of Amikacin 
troughs/week (those on amikacin) (n=58) 
(IQR) 
 1.01 (0.76-1.29) 
*IQR-interquartile range, FLQr=fluroquinolone resistance. 
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Table 3: Multivariable (adjusted) analysis investigating the predictors of hearing loss (composite)  
   Univariate analysis Multivariable analysis 
VARIABLES 
Hearing 
loss (%) 
 
n=34 
(38%) 
No 
hearing 
loss (%) 
n=56 
(62%) 
Hazard ratio p 
Hazard ratio p 
Choice at 
start:  
 
Amikacin (n=53) 
versus 
Capreomycin (n=37) 
29 (55) 24 (45) 5.80(2.23-15.04) <0.001  
5* (14) 32 (86) 
Grouping  
 
 
Starting amikacin (n=53) 
versus 
Capreomycin only (n=30) 
29 (55) 24 (45) 11.70 (2.78-49.20) 0.001 13.85 (3.25-58.99) <0.001 
2 (7) 28 (93) 
Capreomycin followed by 
amikacin (n=7) 
versus 
Capreomycin only (n=30) 
3 (43) 4 (57) 6.29 (1.05-37.65) 0.044 4.03 (0.66-24.63) 0.13 
2 (7) 28 (93) 
Starting amikacin (n=53) 
versus 
Capreomycin followed by 
amikacin (n=7) 
29 (55) 24 (45) 1.86 (0.56-6.13) 0.307 3.44 (0.97-12.18) 0.06 
3 (43) 4 (57) 
MDR-TB 
Type 
MDR+ FLQ-TB (n=12) 
versus 
MDR-TB (n=70) 
8 (67) 4 (33) 3.26(1.44-7.36) 0.005  
22 (31) 48 (69) 
XDR-TB (n=8) 
versus 
MDR TB (n=70) 
4 (50) 4 (50) 1.62 (0.55-4.73) 0.378 
22 (31) 48 (69) 
XDR-TB (n=8) 
versus 
MDR+FLQ-TB (n=12) 
4 (50) 4 (50) 0.55 (0.17-1.83) 0.331 
8 (67) 4 (33) 
FLQ resistance (n=20)  
versus 
MDR TB (n=70) 
12 (60) 8 (40) 2.43 (1.20-4.93) 0.013 3.15(1.45-6.88) 0.004 
22 (31) 48 (69) 
Median dose of injectable at start 
(mg/kg) (IQR) 
14.58 
(13.82-
15.51) 
14.94 
(14.07-
16.63) 
0.84 (0.71-1.00) 0.047  
Median creatinine baseline µmol/L (log 
scale) 
4.25(4.13, 
4.30) 
4.17 
(4.04, 
4.32) 
4.37 (1.12-17.11) 0.034 
Median creatinine clearance 
114.1 
(99.5, 
122.9) 
119.3 
(105.8-
134.5) 
0.98 (0.97, 1.00) 0.055 0.99 (0.97-1.00) 0.11 
Median Age (1 year effect) (IQR) 
28.5 (25-
39) 
27.5 
(22.5-
33.5) 
1.03 (0.99-1.07) 0.127  
*Only two of these cases occurred on capreomycin. The other three occurred on amikacin after they 
had been switched off capreomycin for other reasons. 2 had normal pure tone audiograms (PTA) at 
the start of amikacin. 
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Table 4: Multivariable model for creatinine rise to over 1.5 times baseline and 
hypokalaemia 
 MV model for cratinine rise > 1.5x 
baseline 
MV model for hypokalaemia 
variable Odds Ratios P value Odds ratios P value 
Creatinine baseline 1.02 (0.99-1.05) 0.145  
Amikacin verses 
capreomycin at 
start 
0.44 (0.14-1.45) 0.178 0.28 (0.11-
0.72) 
0.008 
Total duration (30 
days effect) 
1.15 (1.02-1.32) 0.040 1.00 (0.91-
1.08) 
0.869 
 
 
 
 
Figure 1: Flow diagram showing injectable agent use in cohort 
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Figure 2: Predicted proportion surviving without hearing loss by initial choice of injectable 
agent. Middle line (black) represents the predicted proportion and outer lines represent 
95% confidence intervals (red).  
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